COMBINED MODALITY THERAPY TO SUPPRESS PHILADELPHIA CHROMOSOME CELLS IN CML

$79,323P01FY2000CANIH

University Of Texas Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 35201293 Paper 34312462 Paper 33901324 Paper 33283580 Paper 33180322 Paper 31999850 Paper 31999839 Paper 31811114 Paper 31371419 Paper 30885996 Paper 30811597 Paper 30115541 Paper 29773601 Paper 29773593 Paper 29655803 Paper 29545342 Paper 29490944 Paper 29338567 Paper 29296796 Paper 29296774 Paper 29266206 Paper 29091516 Paper 29075538 Paper 29027261 Paper 28972430 Paper 28965757 Paper 28850699 Paper 28835441 Paper 28835440 Paper 28766962 Paper 28743165 Paper 28670739 Paper 28646517 Paper 28608976 Paper 28599188 Paper 28468826 Paper 28452257 Paper 28387922 Paper 28321124 Paper 28278723 Paper 28254787 Paper 28143883 Paper 28105453 Paper 28089238 Paper 27991894 Paper 27980103 Paper 27927766 Paper 27763690 Paper 27727470 Paper 27677095 Paper 27658536 Paper 27654852 Paper 27605552 Paper 27581143 Paper 27551334 Paper 27531525 Paper 27521332 Paper 27509035 Paper 27480386 Paper 27468087 Paper 27463065 Paper 27283492 Paper 27217448 Paper 27175025 Paper 27090958 Paper 27028877 Paper 26993758 Paper 26971533 Paper 26933174 Paper 26929325 Paper 26884599 Paper 26846160 Paper 26837843 Paper 26822154 Paper 26799924 Paper 26796981 Paper 26729897 Paper 26719529 Paper 26688093 Paper 26687797 Paper 26648538 Paper 26582647 Paper 26568194 Paper 26479889 Paper 26459177 Paper 26436949 Paper 26436130 Paper 26434969 Paper 26431162 Paper 26375587 Paper 26372962 Paper 26371140 Paper 26348106 Paper 26217876 Paper 26202934 Paper 26172479 Paper 26048327 Paper 25972343 Paper 25867648 Paper 25840338

Abstract

This project involves clinical investigation of strategies to improve results of chemotherapy and biologic treatment of CML. Aim 1 builds upon the success of the program in defining the activity of interferon-alpha for CML and more recently the combination of interferon and cytarabine. We will test the hypothesis that the combination of interferon-alpha, cytarabine and ATRA improves outcome compared to interferon- alpha/cytarabine treatment. Aim 2 is directed to evaluation of a decitabine, a novel chemotherapeutic agent with a unique mechanism of action to determine if it an induce significant and durable suppression of the Ph-positive cells in late chronic phase CML and/or in interferon alpha (IFN-A) resistant CML disease. The effects of this agent on DNA methylation will be studied and related to the evaluation of epigenetic alterations in Project 9. Aims 3 and 4 are directed to evaluating novel biologic agents in patients failing to have a major response to interferon. Aim 3 develops therapeutic approaches to overcome resistance to interferon-alpha via the inhibition of cellular production of interleukin 1-beta evaluation of interleukin-1 receptor antagonist. In aim 4, the objective is to identify biologics which improve cytogenetic response to interferon. In a pilot study, the combination of interferon- alpha and GM-CSF has produced marked cytogenetic responses in interferon resistant patients; this combination will be studied in a larger phase II trial to evaluate its potential efficacy. This project interacts extensively with he basic science projects within this proposal, particularly, Project 5 (Molecular Sensitization of p210 Bcr-Abl Positive Cells to Therapy), Project 4 (Stem Cell Prognosticators of Sensitivity & Resistance in CML) and Project 9(Epigenetic Alterations in CML).

View original record on NIH RePORTER →